Shareholders at Dublin headquartered Botox-maker Allergan have strongly backed its $63bn takeover by US pharmaceutical company AbbVie.

At a court-ordered meeting of Allergan's shareholders and an extraordinary general meeting in Dublin, this morning over 99% of votes cast backed the deal.

The takeover is due to close early next year.

Abbvie is paying Allergan shareholders with cash and stock as part of the transaction announced last June.

Shareholders in Allergan will receive 0.86 shares in AbbVie and $120 in cash per share.

Allergan has four facilities here, employing around 2,000 staff.

Its Westport campus is the largest and most complex in the company's global network. 
It includes a pharmaceuticals facility, two biologics plants and an ocular implant facility and is also responsible for the global supply of Botox. 

Chicago headquartered AbbVie has five sites in Ireland, including three manufacturing facilities in Sligo and Cork, and two offices in Dublin.

More than 700 people are employed across the various locations.